Zhang S J, Endo S, Ichikawa T, Yoshimura J, Onda K, Tanaka R, Washiyama K, Kumanishi T
Department of Molecular Neuropathology, Brain Research Institute, Niigata University.
Jpn J Cancer Res. 1999 Sep;90(9):934-41. doi: 10.1111/j.1349-7006.1999.tb00838.x.
A total of 10 glioma cell lines were examined to evaluate the status of the MMAC1 gene, a candidate tumor suppressor gene. Six cell lines showed mutations with presumed loss of heterozygosity and 1 cell line showed no mRNA expression. The 6 mutations consisted of 3 3-bp deletions (codons 17, 101 or 199), 1 missense mutation (codon 252) and 2 truncation mutations (1 nonsense mutation at codon 233 and 12-bp insertion at codon 241). Among them, the 3-bp deletions, which are a rare type of mutation in MMAC1 gene, were located in the N-terminal half (codons 1-212) of the coding region, which is considered important in MMAC1 function. The missense mutation was located unusually in the C-terminal half (codons 212-403), but it was in a small region in which some other reported missense mutations are clustered. Thus, these 4 mutations were suggested to have functional effects on the MMAC1 activity, like the other 2 mutations with predicted protein truncations. By sequence analysis of cDNA clones, we confirmed that all the mutations including these 4 rare ones were in the MMAC1 gene, not in the PTH2 pseudogene. In 2 cases, we also examined the primary glioma tissues from which the cell lines had been derived and found the same mutations as in the cell lines in both cases. This suggested that the mutations in these cell lines were derived from the primary glioma tissues, but not from artifacts arising during long-term in vitro cultivation.
共检测了10种胶质瘤细胞系,以评估候选抑癌基因MMAC1的基因状态。6种细胞系显示出假定杂合性缺失的突变,1种细胞系未显示mRNA表达。这6种突变包括3个3碱基缺失(密码子17、101或199)、1个错义突变(密码子252)和2个截短突变(1个密码子233处的无义突变和1个密码子241处的12碱基插入)。其中,3碱基缺失是MMAC1基因中一种罕见的突变类型,位于编码区的N端一半(密码子1-212),这在MMAC1功能中被认为很重要。错义突变异常地位于C端一半(密码子212-403),但处于其他一些报道的错义突变聚集的小区域。因此,这4种突变被认为对MMAC1活性有功能影响,就像其他2种预测有蛋白质截短的突变一样。通过对cDNA克隆的序列分析,我们证实所有突变,包括这4种罕见突变,均存在于MMAC1基因中,而非PTH2假基因中。在2个病例中,我们还检测了细胞系来源的原发性胶质瘤组织,发现2个病例的原发性组织中均存在与细胞系相同的突变。这表明这些细胞系中的突变源自原发性胶质瘤组织,而非长期体外培养过程中产生的人为因素。